JAK2 and neoplasm: To determine whether the activation is specific to JAK inhibition by ruxolitinib, we treated BMDMs with CM from 4T1 tumor cells in presence of Solcitinib (Fig. 3e,f) and NVP-BSK805 (Fig. 3g,h), inhibitors specific for JAK1 and JAK2 respectively48,49.